RefID Author Title Journal RefYear MedlineID Published 64 Condra, JH Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996 8970946 Yes 67 Winters, MA Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. AAC 1997 9087484 Yes 69 Shafer, RW Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997 9188616 Yes 71 Demeter, LM Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type I isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). AAC 2000 10681363 Yes 72 Shafer, RW Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1 - infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995 7541064 Yes 126 Fitzgibbon, JE Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993 8230450 Yes 141 Molla, A Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996 8673921 Yes 168 Shafer, RW Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998 9634429 Yes 173 Shafer, RW Sequence and drug susceptibility of HIV-1 type C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. ARHR 1999 10024054 Yes 176 Markowitz, M A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998 9607830 Yes 177 Winters, MA Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998 9573309 Yes 369 Byrnes, VW Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. AAC 1994 7522428 Yes 410 Dueweke, TJ A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. PNAS 1993 7685109 Yes 414 Emini, EA HIV and multidrug resistance. Nature 1993 7689173 Yes 483 Jacobsen, H Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995 7831807 Yes 497 Kellam, P Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994 7509370 Yes 520 Lacey, SF Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'- dideoxythymidine in cell culture. AAC 1994 7522429 Yes 524 Larder, BA Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993 7692302 Yes 555 Mellors, JW Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. AAC 1995 7542860 Yes 580 Patick, AK Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. AAC 1996 8834868 Yes 631 Shirasaka, T Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. PNAS 1995 7534421 Yes 640 St Clair, MH Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991 1716788 Yes 649 Tisdale, M Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. PNAS 1993 7685907 Yes 705 Patick, AK Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. AAC 1998 9756769 Yes 711 Craig, C HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998 9764779 Yes 718 Winters, MA A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998 9819361 Yes 726 Tisdale, M Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. AAC 1997 9145875 Yes 728 Young, SD L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. AAC 1995 8592986 Yes 730 Larder, BA 3'-Azido-3'-Deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. AAC 1992 1282792 Yes 732 Richman, DD Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. PNAS 1991 1722324 Yes 733 Balzarini, J A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. ARHR 1998 9491916 Yes 736 Shafer, RW Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. AAC 1996 9124861 Yes 738 Kellam, P Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. PNAS 1992 1371886 Yes 742 Palmer, S Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999 10397560 Yes 746 Carrillo, A In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378. J Virol 1998 9696850 Yes 751 Partaledis, JA In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995 7636964 Yes 755 Zolopa, AR HIV-1 genotypic resistance patterns predict response to saquinavir/ritonavir in patients in whom previous protease inhibitor therapy failed. Ann Intern Med 1999 10610625 Yes 756 Shulman, NS Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. JAIDS 2000 10839657 Yes 758 Tisdale, M Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. AAC 1995 7486905 Yes 761 Ho, DD Characterization of human immunodeficiency virus type1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994 8107264 Yes 763 Deeks, SG Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999 10228057 Yes 768 Larder, BA A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. AAC 1999 10428920 Yes 782 Fujiwara, T S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. AAC 1998 9624472 Yes 789 Imamichi, T High-level resistance to 3'-azido-3'-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000 10623768 Yes 792 Pellegrin, I Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999 10509572 Yes 807 Petropoulos, CJ A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. AAC 2000 10722492 Yes 808 Falloon, J Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000 10671334 Yes 810 Hertogs, K A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. AAC 2000 10681319 Yes 813 Ziermann, R A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000 10756056 Yes 817 Miller, V HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000 10708287 Yes 822 Lennerstrand, J Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. AAC 2001 11408240 Yes 823 Sevin, AD Methods for investigating the relationship between drug-susceptibility phenotype and HIV-1 genotype with applications to ACTG 333. J Infect Dis 2000 10882582 Yes 825 Huang, W A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antivir Ther 2000 Yes 840 Huang, W Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003 12502865 Yes 841 Pelemans, H Site-directed mutagenesis of HIV-1 reverse transcriptase at amino acid position 138. Virology 2001 11162823 Yes 845 Gong, YF In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. AAC 2000 10952574 Yes 848 Huang, W Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility. Antivir Ther 1999 Yes 850 Whitcomb, J Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002 12370521 Yes 852 Jorgensen, LB Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine. Antivir Ther 2000 11075938 Yes 853 Vergne, L Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000 11060045 Yes 857 Parkin, NT Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000 11153669 Yes 864 Parkin, NT Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 and 90: Modulatory effects of mutations at secondary positions. ICAAC 2000 2001 Yes 865 Brun, S Patterns of protease inhibitor cross resistance in viral isolates with reduced susceptibility to lopinavir. CROI 2001 2001 Yes 869 Maguire, M Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. AAC 2002 11850255 Yes 870 Gonzales, MJ HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. J Infect Dis 2001 11574914 Yes 874 Walter, H Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Antivir Ther 2000 11142619 Yes 879 Bacheler, LT Genotypic correlates of phenotypic resistance to Efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001 11333879 Yes 891 Van Laethem, K Patient HIV strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS 2000 10770556 Yes 893 Parkin, NT Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of protease inhibitor cross-resistance. Antivir Ther 2001 000000 Yes 906 Kempf, DJ Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001 11462018 Yes 913 Zachary, KC Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin Infect Dis 2001 11700580 Yes 948 Qari, SH Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 2002 11773089 Yes 951 Gonzales, MJ Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003 12660525 Yes 952 Colonno, RJ Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004 15122516 Yes 953 Margot, NA Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002 12045487 Yes 960 Wu, TD Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003 12663790 Yes 967 Dunne, AL Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001 11504978 Yes 968 Ait-Khaled, M Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine, zidovudine in HIV-1 infected adults with no prior antiretroviral therapy. Antivir Ther 2002 12008787 Yes 998 Parkin, NT Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. AAC 2003 14742192 Yes 1024 Roge, BT K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003 12741630 Yes 1027 Gonzales, MJ Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. ARHR 2003 14601580 Yes 1028 Condra, JH In vivo emergence of HIV-1 variants resistant to multiple proteaseinhibitors. Nature 1995 7700387 Yes 1029 Johnston, E Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. AAC 2004 15561868 Yes 1031 Harrigan, PR A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 2002 12050397 Yes 1033 Dumans, AT Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. AAC 2002 12183276 Yes 1035 Mo, H Identification andstructural characterization of I84C and I84A mutations that are associated with high-level resistance to HIV protease inhibitors and impair viral replication. AAC 2006 17101675 Yes 1036 Miller, MD Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine and efavirenz. Antivir Ther 2003 Yes 1039 Romano, L Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 2002 11920313 Yes 1040 Dauber, DS Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol 2002 11773410 Yes 1042 Winters, MA Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. AAC 2001 11451685 Yes 1044 Harrigan, PR Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005 15802972 Yes 1053 Sevigny, G Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res 2006 16473417 Yes 1054 Parkin, NT HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine. IHDRW 2003 2003 Yes 1056 Prado, JG Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002 11953467 Yes 1058 Masquelier, B Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. AAC 2001 11353634 Yes 1062 Kagan, RM Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci 2005 15937277 Yes 1063 Srinivas, RV Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. AAC 1998 9624498 Yes 1064 Harrigan, PR Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996 8709214 Yes 1065 Wainberg, MA In vitro selectin and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999 10682153 Yes 1066 Foli, A In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-{2-(phosphonomethoxy)ethyl}adenine (PMEA). Antiviral Res 1996 8891168 Yes 1079 Bellosillo, N G190A substitution is associated with delavirdine(DLV) hypersusceptibility in vitro and clinical response with DLV intensification. Antivir Ther 2003 Yes 1091 Vidal, C Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther 2002 12553483 Yes 1092 Monno, L HIV-1 phenotypic susceptibility to lopinavir(LPV) and genotypic analysis in LPV/r-Naive subjects with prior protease inhibitor experience. JAIDS 2003 12869832 Yes 1102 Lanier, ER Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004 15544690 Yes 1123 Kuritzkes, DR Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. JAIDS 2004 15097303 Yes 1127 Grossman, Z Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. AAC 2004 15155216 Yes 1129 Gonzales, MJ Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. JAIDS 2003 14615657 Yes 1130 Mueller, SM Susceptibility to saquinavir and atazanavir in highly protease inhibitor(PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V. Antivir Ther 2004 Yes 1131 Sevigny, G Cross-Risistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. IHDRW 2004 2004 Yes 1132 Vergne, L Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003 14565607 Yes 1133 Yates, PJ In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. AAC 2006 16495277 Yes 1134 Delgado, J Genotypic (and phenotypic) predictors of a response to DDI monotherapy in ZDV-experienced patients. Antivir Ther 2004 Yes 1148 Murphy, MD HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J Clin Virol 2004 15072756 Yes 1150 Lam, E Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin Infect Dis 2003 14557976 Yes 1151 Friend, J Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004 15353986 Yes 1153 Rhee, SY Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. AAC 2004 15273130 Yes 1155 Holguin, A Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004 15465415 Yes 1166 Winters, MA Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000 11044115 Yes 1167 Rhee, SY HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance J Infect Dis 2005 15995959 Yes 1168 Johnston, E Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 2005 15821401 Yes 1202 Coakley, E Atazanavir resistance in a protease inhibitor-naive patient treated with atazanavir/ritonavir associated with development of high-level atazanavir resistance and the N88S mutation in protease. CROI 2007 2005 Yes 1210 Mo, H Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005 15731227 Yes 1251 Vidal, N HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). ARHR 2006 16478404 Yes 1253 Agwale, SM Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. ARHR 2006 16438641 Yes 1259 Parkin, NT The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. AAC 2006 16377709 Yes 1263 Doyon, L Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 2005 16122817 Yes 1265 Ross, LL A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine. AIDS 2006 16514317 Yes 1266 Resch, W Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol 2005 16051856 Yes 1276 Koizumi, Y Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. JAIDS 2006 16885781 Yes 1278 Vergne, L Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006 16563858 Yes 1285 Rhee, SY Genotypic predictors of human immunodeficiency virus type 1 drug resistance. PNAS 2006 17065321 Yes 1485 Baxter, JD Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006 16928764 Yes 1495 Ochoa de Echaguen, A Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005 16103769 Yes 1513 McGrath, D Antiviral efficacy and emergent PI substitutions in treatment-naive subjects receiving atazanavir +/- ritonavir-based HAART in subtype b and non-type b HIV-1 infection. IHDRW 2007 2007 Yes 1514 Zolopa, A Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor naive subjects in the IMPACT study (BMS AI424-128). IHDRW 2007 2007 Yes 1516 Andries, K TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. AAC 2004 15561844 Yes 1517 Das, K Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004 15115397 Yes 1518 Vingerhoets, J TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005 16188980 Yes 1519 Su, G In Vitro Selection and Characterization of Viruses Resistant to R1206, a Novel Nonnucleoside Reverse Transcriptase Inhibitor IHDRW 2007 2007 Yes 1539 King, M Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance. IHDRW 2006 2006 Yes 1542 Bradshaw, D Characterization of a novel drug-resistance pattern associated with the mutations K70G and M184V in HIV-1 reverse transcriptase. AAC 2007 17876005 Yes 1581 Eshleman, SH Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. ARHR 2006 16545016 Yes 1620 Poveda, E Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008 18317002 Yes 1645 Vingerhoets, J An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. IHDRW 2008 2008 Yes 1646 De Meyer, S Characterization of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients. CROI 2008 2008 Yes 1649 Das, K High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. PNAS 2008 18230722 Yes 1664 Poveda, E Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008 18981781 Yes 1672 Eshleman, SH Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009 19276794 Yes 1680 Rimsky, LT In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs. IHDRW 2009 2009 Yes 1718 Vingerhoets, J Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010 20051805 Yes 1745 Azijn, H TMC278, a next-generation NNRTI, active against wild-type and NNRTI-resistant HIV-1. AAC 2010 19933797 Yes 1746 Saskova, KG Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol 2009 19535439 Yes 1752 Kagan, RM Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Res 2007 17442410 Yes 1757 Maiga, AI Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. AAC 2010 20008779 Yes 1790 Rhee, SY HIV-1 protease mutations and protease inhibitor cross resistance. AAC 2010 20660676 Yes 1950 Kagan, RM Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 2009 19474648 Yes 1957 Tambuyzer, L Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009 19320243 Yes 1958 Balamane, M NNRTI patient phenotypes unpublished 2012 Yes 1960 Hu, Z Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase JAIDS 2007 17496561 Yes 1961 Kulkarni, R The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness JAIDS 2012 21997204 Yes 1963 Varghese, V 64H samples unpublished 2011 Yes